VIVACITY-MG: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACO-KINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Antozzi, Carlo
- Guptill, Jeffrey
- Bril, Vera
- Gamez, Josep
- Meuth, Sven G.
- Blanco, Jose L. M.
- Nowak, Richard J.
- Quan, Dianna
- Szczudlik, Andrzej
- Hegarty, Brooke
- Jouvin, Marie-Helene
- Jin, Jim
- Arroyo, Santiago
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Antozzi,C,Guptill,J,Bril,V,Gamez,J,Meuth,SG,Blanco,JLM,Nowak,RJ et al. VIVACITY-MG: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE- BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACO-KINETICS, PHARMACODYNAMICS, AND IMMUNOGENICITY OF NIPOCALIMAB ADMINISTERED TO ADULTS WITH GENERALIZED MYASTHENIA GRAVIS. VIA SANTA MARIA 31, 56126 PISA, ITALY:CLINICAL & EXPER RHEUMATOLOGY. 2023 p.p. 498-498.
Portal de investigación